Pharma and Bio in fact know exactly what they want from their contract development and manufacturing organizations: They want it all. In errant thought at the CMO Leadership Awards leads to the conclusion CMOs can’t be good at a few outsourcing services.
You never thought you’d see a headline like that in Outsourced Pharma. But I’ve rarely heard so clearly articulated the need for a deep rationalization for outsourcing. So while this is unusual for us, the industry won’t continue its amazing progress unless clearly understanding the points against as well as our points in support.
“What would happen if you lined up what I'm concerned about, with the concerns of the CMOs?” asks Bob Sheroff, Senior Vice President, Technical Operations at Agios. Well, we are about to do just that at Outsourced Pharma Boston, where Sheroff will discuss: reliability of supply, continuous compliance, and responsiveness.
Thank high-fructose sugar for pulling at least one of the brightest of a new generation into the study of chemistry, potentially the business of pharmaceuticals, and maybe even the field of outsourcing drug development and manufacturing.
For those in drug development and manufacturing outsourcing through the first decade and a half of this new century, it’s now safe to glance back … and finally put an end to an era focused on costs. A look back, and prognosis for what comes next, in an interview with William A. (Al) Kentrup, VP Global Quality Compliance and Systems, Takeda Pharmaceutical Company.
Three pieces for working with contractors and external supply-chains are Communication, Transparency for Problem Resolution, and Benefit Sharing, says William A. (Al) Kentrup, VP Global Quality Compliance and Systems, Takeda Pharmaceutical Company, and former director of corporate quality at Procter and Gamble.
Every organization – and each individual within – has specific needs and objectives for attending industry conferences. Yet, we can identify three overarching criteria: Go where you can meet customers; Go where you can learn; Go where you can participate. Here’s a look at the possibility of putting all three into practice.
According to a new industry report, the major contract development and manufacturing organizations only command a 2-4% market share each. Nonetheless, there is substantial M&A activity in the sector, and it certainly feels like we’re on a cusp of major consolidation. Let’s look at the evidence and momentum.
Not all Outsourced Pharma readers will have had experiences as pronounced as Jennifer Dent’s. But her narrative can spur us to take a look at our own personal – and organizational – missions within the greater biotech and pharma realm, and point to another area where outsourcing drug development and manufacturing professionals can step up our global leadership.
Is your CMO as accomplished at handling high-potency (HP) compounds as you think? Perhaps you’d better learn to separate "the contenders from the pretenders.” Here’s how.